KDventures: Out of the Shadow, Into the Light - Redeye

Redeye initiates coverage of KDventures, a uniquely VC-style listed investment company focused on biotech. After a period of share price decline, correlated with poor biotech market sentiment, the share is positioned for a turnaround. With a slimmer cost profile and a cash position strengthened by a rights issue this year, the share is set up for a strong recovery upon positive phase IIa data from its crown jewel, Umecrine, in early H2.

Länk till analysen i sin helhet: https://www.redeye.se/research/1165173/kdventures-out-of-the-shadow-into-the-light?utm_source=finwire&utm_medium=RSS